Valiant Organics Ltd

- Currently, Valiant Organics Limited does not have any immediate plans to raise more debt. - Debt repayment is ongoing as per schedule, with about INR 40-45 crores expected to be repaid in the current financial year. - The company plans to fund its current capex primarily through internal accruals without raising additional debt for now. - If there is a future need to raise more debt, the company will consider that option at that time. - Regarding equity, a subsidiary named Valiant Advanced Sciences is planning to raise funds through a greenfield project and has given intimation of a possible public issue. - The parent company itself has not mentioned any equity fundraising in the current discussions.

- Capex for FY '24 and FY '25 is projected around INR 100 crores to INR 110 crores annually, mainly for brownfield expansion, maintenance, and debottlenecking. - No major new projects like PAP or Pharma Intermediates; focus on adding new products, especially in chlorination and ammonolysis segments. - Some redevelopment and capacity improvement ongoing at Ahmedabad facility. - Debottlenecking at Sarigam chlorination plant considered, but no specific capex or capacity numbers disclosed yet. - Valiant Advanced Sciences, a subsidiary of Valiant Laboratories, plans a greenfield expansion project and is looking to raise funds, possibly through a public issue. - Capex mainly funded internally with no immediate plans to raise new debt, but options considered if needed. - Ongoing loan repayments expected around INR 40-45 crores next year, reducing overall debt.

- FY '24 revenue guidance on a standalone basis is around INR 1,200 crores, implying 30%-35% growth. - Pharma Intermediates revenue expected to reach INR 55 crores in FY '24, phasing up to peak of INR 65-70 crores. - PAP (paracetamol) volumes targeted to scale from ~400 tons/month to 500 tons/month by Q2 FY '24, then progressively to 700-750 tons/month by year-end, aiming for INR 250-300 crores revenue. - Overall capacity utilization expected to increase in Sarigam unit from ~60% to 80-85% in the year, supporting agrochemical segment growth. - New product additions in chlorination and ammonolysis segments planned, supported by INR 100-110 crores annual capex, mostly for brownfield expansions and debottlenecking. - Volume growth is expected month-on-month, but exact percentages are uncertain; some segments like dyes remain subdued. - They target sustaining EBITDA margins around 20% in FY '24 with possible growth beyond 22-25% if significantly accretive products are added.

- EBITDA margin guidance is targeted around 22% to 25% in the medium term, though unlikely to exceed 25% without significant new EBIT-accretive additions. (Page 18, 17) - For FY24, the company expects EBITDA margins around 18% to 20%, aiming for standardized margins of 20%-25% eventually. (Pages 7, 5, 18) - Revenue for standalone business is expected around INR 1,200 crores in FY24 with a 30%-35% growth assumption. (Page 11) - Existing facility revenue potential is estimated between INR 1,300 crores to INR 1,500 crores in 2-3 years with no major capex. (Page 14) - Capex of around INR 100-110 crores annually planned mainly for brownfield expansions and maintenance; not for major capacity additions. (Pages 13, 14, 10) - PAP plant scaling up, aiming for INR 250-300 crores revenue this year, with expectations to grow further. (Pages 10, 12) - Profit cautious due to external factors but optimistic on gradual margin and revenue recovery over next 2-3 years. (Pages 16, 4)

- The transcript does not explicitly state the current or expected order book value or pending orders quantitatively. - Mihir Shah mentions challenges in getting certain products, like OAP, up and running, affecting timelines but not order backlog specifics. - The Sarigam plant is operating well with chlorination demand stable and capacity at around 80-85%, indicating healthy order inflow. - For PAP, volumes averaged around 400 tons per month in Q4, expected to scale to 700-750 tons per month by year-end, reflecting strong order demand. - The company mentions quarterly contracts with customers, indicating ongoing order replenishment but without specific pending order data. - The dialogue suggests steady demand in most segments, with caution on dyes and pigments due to weak industry conditions. - Overall, while no exact order book figures are given, the company is scaling production progressively and managing orders through quarterly contracts.